Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results
May 10, 2021 16:01 ET
|
Gain Therapeutics
Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team ---Signed a multi-target...
Gain Therapeutics Presents Positive In Vitro & In Vivo Data on Its Orally Bioavailable Brain Penetrant Star Compounds for the Treatment of GBA1 Parkinson’s Disease & Related α-synucleopathies at the XXVI IAPRD World Congress
May 03, 2021 07:30 ET
|
Gain Therapeutics
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase ...
Gain Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference
April 27, 2021 16:01 ET
|
Gain Therapeutics
BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing...
Gain Therapeutics Announces Presentation at the International Association of Parkinsonism and Related Disorders 2021 World Congress
April 22, 2021 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., April 22, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing...
Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals
April 20, 2021 08:00 ET
|
Gain Therapeutics
Collaboration to use Gain’s proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously difficult-to-drug oncology targets ...
Gain Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option to Purchase Additional Shares
March 25, 2021 17:57 ET
|
Gain Therapeutics
BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full...
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
March 18, 2021 07:00 ET
|
Gain Therapeutics
BETHESDA, Md., March 18, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of 3,636,364 shares of its common stock at a price of...
Gain Therapeutics Files Registration Statement with SEC for Proposed Initial Public Offering
March 10, 2021 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., March 10, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial public offering of shares of its common stock....
Gain Therapeutics Presents Positive Pre-Clinical Data Supportive of In Vitro Target Engagement for Gaucher Disease, GM1 Gangliosidosis and Morquio B Programs at the 17th Annual WORLDSymposium™
February 11, 2021 08:36 ET
|
Gain Therapeutics
STAR candidates for the treatment of Gaucher Disease enhance GCase activity in a neuronal cell model and reduce toxic accumulation of GCase substrate STAR candidates for the treatment of GM1...
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
February 04, 2021 08:00 ET
|
Gain Therapeutics
BETHESDA, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites...